AI Solutions for Pharma. From Drug Discovery to Commercialization

The strongest AI use cases in pharma are those that reduce expert workload, improve decision quality, and integrate into regulated workflows. Based on deepsense.ai case studies, the most concrete opportunities are:

AI for drug discovery — multimodal models for in-silico drug discovery, molecular property prediction, chemistry-aware assistants, and experiment analysis. In one case, deepsense.ai integrated Llama 3.1 with Graphormer to help researchers analyze text, SMILES, and molecular graph data, achieving a 2–5x Graphormer training speedup and reducing overall training time by 50%.

AI in clinical trials — protocol design, site selection, patient enrollment forecasting, RWE/RWD analysis, diversity metrics, and trial planning dashboards. In a clinical trial site selection case, 90% of model-recommended sites outperformed legacy selections in the US market, with over 70 clinical managers using the dashboard across global planning teams.

AI for protocol design — LLM/RAG systems that generate guideline-aware study protocol drafts aligned with internal standards and ENCePP-style structure. One deepsense.ai solution reduced first-pass protocol drafting from months to weeks by combining LLMs with RAG over PubMed, Semantic Scholar, ClinicalTrials.gov, and internal databases.

AI for market access and reimbursement — copilots for drug pricing negotiations, reimbursement research, HTA-style evidence analysis, and competitor outcome synthesis. A deepsense.ai RAG-powered Pricing Copilot helped a pharma team analyze past cases, competitor outcomes, and complex drug data, significantly reducing preparation time for reimbursement negotiations.

AI for medical affairs and compliant content generation — automated literature review, evidence synthesis, MLR-ready promotional content, structured report generation, and validation workflows. In one pharma-compliant content case, deepsense.ai built an OCR + multimodal LLM + agent validation pipeline for MLR-ready outputs, achieving a completeness score of 0.87 and a hallucination detection score of 0.85.

AI can improve clinical trials by making planning, protocol design, site selection, patient enrollment, and evidence generation more data-driven and repeatable. The biggest gains come when AI integrates real-world data, historical trial data, clinical registries, and internal operational data into decision-support workflows.

For site selection, deepsense.ai built a modular AI platform using RWD, clinical trial databases, external datasets, and internal data to recommend trial sites based on enrollment potential, diversity scores, and historical performance. The system included supervised ML models, automated evaluation pipelines, and a dashboard used by over 70 clinical decision-makers.

For protocol design, AI can shorten authoring cycles by generating structured, guideline-aware drafts that clinical and scientific teams can review and refine. deepsense.ai’s ENCePP-aligned protocol generation system produced complete protocol drafts across sections such as objectives, study design, population, data sources, outcomes, analysis, and ethics, while integrating evidence retrieval from PubMed, Semantic Scholar, ClinicalTrials.gov, and internal sources.

GxP-compliant AI does not mean “the model is compliant” on its own. It means the AI system, workflow, data handling, validation evidence, monitoring, and human review process are designed for regulated use.

In practical terms, regulated AI for pharma should include:

• clearly defined intended use
• risk-based validation or computer software assurance
• audit trails and traceability
• data integrity controls
• access control and security
• documented evaluation results
• change management and versioning
• monitoring after deployment
• human-in-the-loop review where required

This aligns with FDA guidance on computer software assurance, which describes a risk-based approach to establishing confidence in automation used in production or quality systems and emphasizes objective evidence to support validation requirements. FDA data integrity guidance also defines an audit trail as a secure, computer-generated, time-stamped electronic record that allows reconstruction of record creation, modification, or deletion.

AI copilots support market access teams by helping them prepare faster for reimbursement, pricing, HTA, and negotiation workflows. Instead of manually searching through long documents, previous submissions, competitor outcomes, clinical evidence, and drug-specific data, teams can use a RAG-powered copilot to retrieve, summarize, compare, and synthesize relevant information.

A strong example is deepsense.ai’s AI Copilot for Drug Pricing Negotiations. The system was designed for a pharma leader preparing for reimbursement negotiations and used long-context processing with RAG to analyze extensive documentation, including past cases, competitor outcomes, and complex drug data. The result was faster preparation, better-informed decisions, and more effective negotiation support.

Yes — but only when generative AI is implemented as a controlled system, not as an open-ended chatbot. Safe generative AI for pharma requires RAG, evaluation, auditability, access control, human review, monitoring, and deployment architecture aligned with regulatory and security requirements.

deepsense.ai’s pharma-compliant content generation case is a good example. The system combined Azure OCR, multimodal GPT-4.1, structured element-level processing, agent-based validation, and a custom evaluation framework to reduce hallucination risk and prepare content for MLR review. The architecture separated OCR processing from the review workflow, improved scalability, and supported auditable, regulated content production.

The EMA also frames AI in medicines regulation as a way to support research, process automation, better data insights, and decision support — while managing risk across the medicinal product lifecycle.